Kinga Winiarczyk

The Maria Sklodowska-Curie National Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Dariusz M. Kowalski

The Maria Sklodowska-Curie National Research Institute of Oncology

Maciej Krzakowski

The Maria Sklodowska-Curie National Research Institute of Oncology

Magdalena Knetki‐Wróblewska

The Maria Sklodowska-Curie National Research Institute of Oncology

Aleksandra Piórek

The Maria Sklodowska-Curie National Research Institute of Oncology

Janusz Milanowski

Medical University of Lublin

Paweł Krawczyk

Medical University of Lublin

Adam Płużański

The Maria Sklodowska-Curie National Research Institute of Oncology

Sylwia Tabor

The Maria Sklodowska-Curie National Research Institute of Oncology

Tomasz Powrózek

Medical University of Lublin

Piotr Jaśkiewicz

The Maria Sklodowska-Curie National Research Institute of Oncology

Cooperative Institutions

Centrum Onkologii

The Maria Sklodowska-Curie National Research Institute of Oncology

Microsoft (Brazil)

Medical University of Lublin

Poznan University of Medical Sciences

National Institute of Oncology

Medical University of Warsaw

National Institute of Public Health

Foundation for Polish Science

University of Pittsburgh

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

1485P Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice

Annals of Oncology (2023)

Magdalena Knetki‐Wróblewska Aleksandra Piórek Sylwia Tabor Kinga Winiarczyk Paweł Sobczuk

Log-rank test

Progression-free survival

Univariate analysis

10.1016/j.annonc.2023.09.2516

Cite

Citations (0)

Treatment of Pulmonary Artery Stump Thrombosis after Lobectomy: A Case Report and Literature Review

Advances in respiratory medicine (2021)

Maria Wieteska Kinga Winiarczyk Włodzimierz Kupis

Introduction: Lung cancer surgery is a well-known risk factor for venous thromboembolism. Thus, standard care involves the use of pharmacological and mechanical prophylaxis until discharge from the hospital. Pulmonary artery stump thrombosis (PAST) is a rare condition which can develop months to years after lung cancer surgery. This report describes a patient diagnosed with PAST and the decisions that were made regarding his treatment. Case report: A 67-year-old male was diagnosed with lung cancer due to shortness of breath, dry cough, hemoptysis, and typical chest computed tomography (CT) findings. He underwent right lower lobectomy and mediastinal lymphadenectomy by video-assisted thoracoscopic surgery. The procedure was complicated by the development of a right pleural empyema. After pleural drainage and an antibiotic regimen, he was discharged from the hospital with further improvement. A follow-up CT pulmonary angiography performed three months after lobectomy revealed thrombosis in the right lower lobar pulmonary artery stump. The patient had no symptoms. The attending physician decided to use anticoagulants. Consequently, the patient received low molecular-weight heparin subcutaneously for one month and a non-vitamin-K antagonist oral anticoagulant (NOAC) for the following 5 months. A CT scan performed after 3 months of anticoagulation showed complete resolution of stump thrombosis. Subsequent examinations showed no recurrence of either lung cancer or artery stump thrombosis and no anticoagulant-related bleeding. Discussion: Pulmonary artery stump thrombosis can develop after lung cancer surgery. This complication is uncommon and the prognosis is favorable in most treated cases. However, thrombosis may progress, and pulmonary embolism or chronic thromboembolic pulmonary hypertension may develop. Decisions about instituting anticoagulation therapy and its duration are made on an individual basis after considering both the benefits and the potential risks

10.5603/arm.a2021.0010

Cite

Citations (5)

Use of next-generation sequencing in daily routine practice

Oncology in Clinical Practice (2023)

Adam Płużański Andrzej Tysarowski Maciej Kawecki Jakub Kucharz Kinga Winiarczyk

Developments in molecular diagnosis and implementation of mutation-driven targeted therapy marked a milestone in cancer treatment. Next-generation sequencing allows sequencing of a high number of nucleotides in a short time and from a limited quantity of pathology or cytology specimens. This is a review of actual indications, utility of next-generation sequencing, and availability of targeted therapies in different neoplasms. We present the European Society for Medical Oncology Precision Medicine Working Group recommendations for tumor multigene sequencing use with the Scale for Clinical Actionability of molecular Targets ranking determined for each alteration.

Milestone

Precision oncology

Molecular diagnostics

Molecular Pathology

Targeted Therapy

10.5603/ocp.2023.0001

Cite

Citations (0)

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations

Oncology Letters (2017)

Paweł Krawczyk Dariusz M. Kowalski Rodryg Ramlau Ewa Kalinka‐Warzocha Kinga Winiarczyk

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of the EGFR gene. The aim of the study was to compare the efficacies of EGFR-TKIs in patients with common (exon 19 deletions and exon 21 p.Leu858Arg) and rare EGFR mutations. A retrospective analysis of 180 NSCLC patients with common (n=167) and rare (n=13) EGFR mutations treated with erlotinib (n=98), gefitinib (n=66) and afatinib (n=16) was performed. EGFR mutations were determined using RT-PCR and the EntroGen EGFR Mutations Analysis kit. Partial and complete response (PR and CR), progression-free survival (PFS), and overall survival (OS) were analyzed. Demographic and clinical factors had no impact on PFS or OS in patients treated with EGFR-TKIs. Erlotinib, gefitinib, and afatinib showed similar efficacies based on treatment response, median PFS, and OS. The type of EGFR mutation had no impact on median OS; however, median PFS was significantly longer in patients with the exon 19 deletion compared to patients with the exon 21 p.Leu858Arg substitution and rare EGFR gene mutations (P=0.013). Patients with common EGFR mutations showed significantly longer median PFS than those with rare EGFR mutations (10 vs. 5 months; P=0.009). Erlotinib, gefitinib, and afatinib show similar efficacies in NSCLC patients with both common and rare EGFR mutations. When undergoing EGFR-TKI treatment, patients with rare EGFR mutations showed similar OS but poorer PFS. Further investigation into the associations between particular rare EGFR mutations and EGFR-TKIs treatment outcomes is required.

Afatinib

10.3892/ol.2017.5980

Cite

Citations (59)

Front & Back Matter

Chemotherapy (2012)

Paweł Krawczyk Dariusz M. Kowalski Kamila Wojas‐Krawczyk Radosław Mlak Piotr Jaśkiewicz

10.1159/000337824

Cite

Citations (0)

Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature

Diseases (2024)

Aleksandra Piórek Adam Płużański Piotr Wiśniewski Sylwia Tabor Kinga Winiarczyk

Pulmonary benign metastasizing leiomyoma (PBML) is a rare condition characterized by the spread of uterine leiomyomas to the lungs, typically observed in premenopausal women with a history of hysterectomy or myomectomy. This report presents a unique case of a postmenopausal woman, aged 65, that emphasizes the clinical, radiological, histologic, and immunohistochemical aspects of the disease. On presentation, the patient suffered from severe pain. On imaging, a sizable lung tumor was found. Histopathological examination and immunoprofiling confirmed PBML. The patient underwent various treatments, including surgery, radiation therapy, and hormonal therapy, illustrating the challenges in managing PBML. A literature review underscores the rarity of PBML and its diverse clinical manifestations. This study provides valuable insights into the complexities of PBML.

Presentation (obstetrics)

Uterine Leiomyoma

Rare disease

10.3390/diseases12080181

Cite

Citations (0)

Inhibitory kinaz tyrozynowych ALK/ROS1 oraz EGFR kolejnych generacji w leczeniu zaawansowanego niedrobnokomórkowego raka płuca

Onkologia w Praktyce Klinicznej - Edukacja (2018)

Kinga Winiarczyk Aleksandra Piórek Maciej Krzakowski

Niedrobnokomorkowy rak pluca (NDRP) jest najczestszym nowotworem u mezczyzn i drugim co do czestości u kobiet. W ubieglych latach udowodniono znaczenie niektorych zaburzen molekularnych w patogenezie NDRP i wykazano wartośc terapii celowanych w leczeniu chorych. U osob z zaburzeniami genow EGFR , ALK i ROS1 mozliwe jest wykorzystanie odpowiednich inhibitorow kinaz tyrozynowych (TKI). Zastosowanie wymienionych lekow w pierwszej i drugiej linii leczenia wplynelo na istotną poprawe rokowania w tej podgrupie chorych. W artykule przedstawiono mechanizmy dzialania i dane na temat klinicznej wartości lorlatynibu, brygatynibu i dakomitynibu w leczeniu chorych na zaawansowanego NDRP.

Source

Cite

Citations (0)

Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients

Clinical Lung Cancer (2014)

Tomasz Powrózek Dariusz M. Kowalski Paweł Krawczyk Rodryg Ramlau Tomasz Kucharczyk

Pemetrexed

ERCC1

Chemotherapy regimen

10.1016/j.cllc.2014.06.009

Cite

Citations (6)

Primary thymic tumors — state of the art

Oncology in Clinical Practice (2012)

Kinga Winiarczyk Magdalena Knetki‐Wróblewska Dariusz M. Kowalski Maciej Krzakowski

Thymic malignancies are rare epithelial tumors — they constitute 0.2–1.5 of all neoplasms. Clinical stageand histological type are predictores of outcome. Surgery is the mainstay of the curative-intent treatmentof thymic tumors, in some cases adjuvant chemotherapy or radiotherapy are necessary. Multiagentchemotherapy — based on cisplatin, cycklophosphamid and doxorubicin — is indicated for patientwith recurrent or metastatic disease. Patients with positive somatostatin receptor scintigraphy positivetumors can be also treated with somatostatin analogues. Targeted therapies, such a belinostate, erlotinib,imatinib, are under investigation.

Imatinib Mesylate

Source

Cite

Citations (0)

ALK, ROS1 and EGFR next-generation tyrosine kinase inhibitors in advanced non-small-cell lung cancer

Oncology in Clinical Practice (2019)

Kinga Winiarczyk Aleksandra Piórek Maciej Krzakowski

Non-small-cell lung cancer (NSCLC) is the most common cancer in men and the second most common in fe- males. In previous years the significance of some molecular disorders in pathogenesis NSCLC was proven and the value of targeted therapies in the treatment of patients was documented. In subjects with abnormalities of EGFR , ALK and ROS1 genes, appropriate tyrosine kinase inhibitors (TKIs) may be used. The use of these drugs in the first and second treatment lines has affected a significant improvement in the prognosis in this subgroup of patients. The article presents mechanisms of action and data on the clinical value of lorlatinib, brigatinib and dacomitinib in the treatment of patients with advanced lung of lung cancer.

Pathogenesis

Targeted Therapy

10.5603/ocp.2018.0042

Cite

Citations (0)